Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the efficacy and safety of flexibly dosed
adjunctive brexpiprazole treatment in subjects with major depressive disorder and anxiety
symptoms, who are experiencing an inadequate selective serotonin reuptake inhibitor
(SSRI)/serotonin norepinephrine reuptake inhibitor (SNRI) response.
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.